Episode 422: 429. Rivaroxaban vs Apixaban = The Battle of the Blood Thinners!

— rivaroxaban versus apixaban.

Yes, folks, this is The Battle of the Blood Thinners!

And spoiler alert — one of them came out looking like the overachiever in a safety class... while the other probably needs a little extra padding on its report card.

The Setup

So here’s the story. For years, observational studies hinted that apixaban — we’ll call it “Api” because we’re friendly like that — might be gentler when it comes to bleeding compared to rivaroxaban — or “Riva,” who sounds like she’d stir drama on a reality show.

But now, for the first time ever, we’ve got a head-to-head trial. Picture a randomized cage match… but with 2,800 patients who probably just wanted their deep vein thrombosis or pulmonary embolism treated quietly.

These brave participants, average age 58, were split—half got apixaban, half got rivaroxaban. Researchers then followed them for three suspense-filled months.

The Results (and the Punchline)

Here’s the headline:
Clinically relevant bleeding was twice as likely with rivaroxaban compared to apixaban.
Yup—7.1% versus 3.3%. That’s a difference big enough to make any hematologist clutch their coffee mug a little tighter.

And if you love a good number — the number needed to harm here is 26. That means for every 26 patients you put on rivaroxaban instead of apixaban, one extra person might have a bleeding episode you wish hadn’t happened.

Major bleeding? Rivaroxaban also took home that dubious award — 2.4% versus 0.4%.
Ouch. That’s like comparing a paper cut to an artery leak.
Why the Difference?

The researchers think rivaroxaban’s longer initial high-dose period may explain the extra bleeding drama early in treatment.